Compugen reports positive results from early stage cancer study

Israeli-based Compugen says that its novel immune checkpoint treatment for solid tumors has showed “encouraging signals” in an early stage study.

The company said that its treatment, currently called COM701, is being studied alone and in conjunction with Bristol-Myers Squibb’s immunotherapy Opdivo on patients with advanced solid tumors who have not responded to all standard courses of care. All told, about 75 percent of patients taking COM701 with Opdivo showed “encouraging signals of anti-tumor activity,” compared to 69 percent taking the medication alone. COM701 was also shown to be well-tolerated with no dose-limiting toxicities.

 COM701 targets PVRIG, a novel checkpoint inhibitor discovered by Compugen, which specializes in immunotherapies. 

Read the Reuters report.